Erythropoietin pharmacokinetics in premature infants: Developmental, nonlinearity, and treatment effects

Journal of Applied Physiology

Volumn 80, Issue 1, 1996, Pages 140-148

  Widness, John A ^a   Veng Pedersen, Peter ^a   Peters, Charles ^a   Pereira, Luis M ^a   Schmidt, Robert L ^a   Lowe, Lance S ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

anemia; erythrocyte transfusion; noncompartmental system analysis

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; ERYTHROCYTE TRANSFUSION; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; NEWBORN ANEMIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERY LOW BIRTH WEIGHT;

EID: 0030025407     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.1996.80.1.140     Document Type: Article

References (32)

1. Akaike, H. Automatic control: a new look at the statistical model identification. IEEE Trans. 19: 716-723, 1974.
2. Besarab, A., K. K. Flaharty, A. J. Erslev, and J. B. McCrea. Clinical pharmacology and economics or recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous admininstration. J. Am. Soc. Nephrol. 2: 1405-1416, 1992.
3. Bröckmoller, J., J. Köchling, W. Weber, M. Looby, I. Roots, and H. H. Neumayer. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br. J. Clin. Pharmacol. 34: 499-508, 1992.
4. Brown, M. S., J. F. Garcia, R. H. Phibbs, and P. R. Dallman. Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity. J. Pediatr. 105: 793-798, 1984.
5. Brown, M. S., M. A. Jones, R. K. Ohls, and R. D. Christensen. Single-dose pharmacokinetics of recombinant human erythropoietin in preterm infants after intravenous and subcutaneous administration. J. Pediatr. 122: 655-657, 1993.
6. Cahan, C., M. Decker, J. Arnold, L. Washington, J. Veldhuis, E. Goldwasser, and K. Strohl. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J. Appl. Physiol. 72: 2112-2117, 1992.
7. Carnielli, V., G. Montini, R. DaRiol, R. Dall'Amico, and F. Cantarutti. Effect of high doses of human recombinant erythropoietin on the need for blood transfusions in preterm infants. J. Pediatr. 121: 98-102, 1992.
8. Christensen, R. D. Recombinant erythropoietic growth factors as an alternative to erythrocyte transfusion for patients with "anemia of prematurity." Pediatrics 83: 793-795, 1989.
9. Emmanouel, D. S., E. Goldwasser, and A. I. Katz. Metabolism of pure human erythropoietin in the rat. Am. J. Physiol. 274 (Renal Fluid Electrolyte Physiol. 43): F168-F176, 1984.
10. George, J. W., C. Bracco, K. Shannon, R. Phibbs, J. Davis, I. Smith, and A. Hendrickx. Response of rhesus monkeys to recombinant human erythropoietin: comparison of adults and infants. Pediatr. Res. 28: 567-571, 1990.
11. Georgieff, M. K., M. B. Landon, M. M. Mills, B. E. Hedlund, A. E. Faassen, R. L. Schmidt, J. J. Ophoven, and J. A. Widness. Abnormal iron distribution in infants of diabetic mothers: spectrum and maternal antecedents. J. Pediatr. 117: 455-461, 1990.
12. Gruslin-Giroux, A. R., L. E. Shields, J. A. Widness, and R. A. Brace. Positive correlation between fetal plasma iron and red cell mass restoration in anemic fetuses. J. Soc. Gyn. Invest. 2: 332, 1995
13. Hudson, I. R. B., I. A. J. Cavill, A. Cooke, B. M. Holland, T. G. Hoy, D. Trevett, T. L. Turner, and C. A. J. Wardrop. Biotin labeling of red cells in the measurement of red cell volume in preterm infants. Pediatr. Res. 28: 199-202, 1990.
14. Jelkmann, W. Erythropoietin: structure, control of production, and function. Physiol. Rev. 72: 449-489, 1992.
15. Jensen, J. D., J. W. Jensen, J. K. Madsen, and L. Poulsen. The metabolism of erythropoietin in liver cirrhosis patients compared to healthy volunteers. Eur. J. Haematol. 54: 111-116, 1995.
16. Kinoshita, H., N. Ohishi, M. Kato, S. Tokura, and A. Okazaki, Pharmacokinetics and distribution recombinant erythropoietin in rats. Drug Res. 42: 174-178, 1992.
17. Kling, P. J., J. A. Widness, E. N. Guillery, P. Veng-Pedersen, C. Peters, and P. A. deAlarcon. Pharmacokinetics and pharmacodynamics of erythropoietin during therapy in an infant with renal failure. J. Pediatr. 121: 822-825, 1992.
18. MacDougall, I. C., R. D. Hutton, G. A. Coles, and J. D. Williams. Clinical pharmacokinetic of epotin (recombinant human erythropoietin). Clin. Pharmacokin. 20: 99-113, 1991.
19. Obladen, M., R. Maier, H. Segerer, E. L. Grauel, B. M. Holland, G. Stewart, G. Jorch, H. Rabe, O. Linderkamp, H. G. Hoffmann, F. Houghton, Z. Herrmann, P. Scigalla, and C. Wardrop. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. In: Erythropoietin in Renal and Non-Renal Anemias. Basel: Karger, 1991, p. 314-326.
20. Ohls, R. K., K. A. Osborne, and R. D. Christensen. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J. Pediatr. 126: 421-426, 1995.
21. Ohls, R. K., M. W. Veerman, L. Mandell, and R. D. Christensen. Pharmacokinetics of recombinant erythropoietin administered to preterm infants by continuous infusion in parenteral nutrition solution (Abstract). Pediatr. Res. 37: 79A, 1995.
22. Piroso, E., A. J. Erslev, K. K. Flaharty, and J. Caro. Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows. Am. J. Hematol. 36:105-110, 1991.
23. Ruth, V., J. A. Widness, G. K. Clemons, and K. Raivio. Postnatal changes in serum immunoreactive erythropoietin in relation to hypoxia before and after birth. J. Pediatr. 116: 950-954, 1989.
24. Shannon, K. M., J. F. Keith, W. C. Mentzer, R. A. Ehrenkrantz, M. S. Brown, J. A. Widness, C. A, Gleason, E. M. Bifano, D. D. Millard, C. B. Davis, D. K. Stevenson, D. C. Alverson, C. F. Simmons, M. Brim, R. I. Abels, and R. H. Phibbs. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 95: 1-8, 1995.
25. Shannon, K. M., W. C. Mentzer, R. I. Abels, P. Freeman, N. Newton, D. Thompson, S. Sniderman, R. Ballard, and R. H. Phibbs. Recombinant human erythropoietin in anemia of prematurity: preliminary results of a double-blind placebo controlled pilot study. J. Pediatr. 118: 949-955, 1991.
26. Spivak, J. L., and B. B. Hogans. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73: 90-99, 1989.
27. Stockman, J. A., III, J. E. Graebe, D.A. Clark, K. McClellan, J. F. Garcia, and R. E. W. Kavey. Anemia of prematurity: determinants of the erythropoietin response. J. Pediatr. 105: 786-792, 1984.
28. Veng-Pedersen, P. Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J. Pharmacokinet. Biopharm. 5: 513-031, 1977.
29. Veng-Pedersen, P. System approaches in pharmacokinetics. I. Basic concepts. J. Clin. Pharmacol. 28: 1-5, 1988.
30. 125I-erythropoietin (EPO) elimination is unchanged following liver bypass. Exp. Hematol. 22: 704, 1994.
31. Widness, J. A., P. Veng-Pedersen, N. B. Modi, R. L. Schmidt, and D. H. Chestnut. Developmental differences in erythropoietin pharmacokinetics: increased clearance and distribution in fetal and neonatal sheep. J. Pharmacol. Exp. Ther. 261: 977-984, 1992.
32. Wilimas, J. A., and W. M. Crist. Erythropoietin - not yet a standard treatment for anemia of prematurity. Pediatrics 95: 9-10, 1995.